Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 238

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation

Open access
Kirchhof, Paulus, Haeusler, Karl Georg, Blank, Benjamin, De Bono, Joseph, Callans, David, Elvan, Arif, Fetsch, Thomas, Van Gelder, Isabelle C, Gentlesk, Philip, Grimaldi, Massimo, Hansen, Jim, Hindricks, Gerhard, Al-Khalidi, Hussein R, Massaro, Tyler, Mont, Lluis, Nielsen, Jens Cosedis, Nölker, Georg, Piccini, Jonathan P, De Potter, Tom, Scherr, Daniel, Schotten, Ulrich, Themistoclakis, Sakis, Todd, Derick, Vijgen, Johan, Di Biase, Luigi·2018·European Heart Journal

Abstract

Aims: It is recommended to perform atrial fibrillation ablation with continuous anticoagulation. Continuous apixaban has not been tested. Methods and results: We compared continuous apixaban (5 mg b.i.d.) to vitamin K antagonists (VKA, international normalized ratio 2-3) in atrial fibrillation patients at risk of stroke a prospective, open, multi-centre study with blinded outcome assessment. Primary outcome was a composite of death, stroke, or bleeding (Bleeding Academic Research Consortium 2-5). A high-resolution brain magnetic resonance imaging (MRI) sub-study quantified acute brain lesions. Cognitive function was assessed by Montreal Cognitive Assessment (MoCA) at baseline and at end of follow-up. Overall, 674 patients (median age 64 years, 33% female, 42% non-paroxysmal atrial fibrillation, 49 sites) were randomized; 633 received study drug and underwent ablation; 335 undertook MRI (25 sites, 323 analysable scans). The primary outcome was observed in 22/318 patients randomized to apixaban, and in 23/315 randomized to VKA {difference -0.38% [90% confidence interval (CI) -4.0%, 3.3%], non-inferiority P = 0.0002 at the pre-specified absolute margin of 0.075}, including 2 (0.3%) deaths, 2 (0.3%) strokes, and 24 (3.8%) ISTH major bleeds. Acute small brain lesions were found in a similar number of patients in each arm [apixaban 44/162 (27.2%); VKA 40/161 (24.8%); P = 0.64]. Cognitive function increased at the end of follow-up (median 1 MoCA unit; P = 0.005) without differences between study groups. Conclusions: Continuous apixaban is safe and effective in patients undergoing atrial fibrillation ablation at risk of stroke with respect to bleeding, stroke, and cognitive function. Further research is needed to reduce ablation-related acute brain lesions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehy176

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 238

Metadata

Authors
Kirchhof, P., Haeusler, K. G., Blank, B., De Bono, J., Callans, D., Elvan, A., Fetsch, T., Van Gelder, I. C., Gentlesk, P., Grimaldi, M., Hansen, J., Hindricks, G., Al-Khalidi, H. R., Massaro, T., Mont, L., Nielsen, J. C., Nölker, G., Piccini, J. P., De Potter, T., Scherr, D., Schotten, U., Themistoclakis, S., Todd, D., Vijgen, J., & Di Biase, L.
Venue
European Heart Journal
Published
2018-03-20
Volume
39
Issue
32
Pages
2942-2955
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2792300635
Cited by
238
References
6
FWCI
23.05
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. https://app.cochat.ai/papers/10.1093/eurheartj/ehy176
The paper
Kirchhof, P., Haeusler, K. G., Blank, B., De Bono, J., Callans, D., Elvan, A., Fetsch, T., Van Gelder, I. C., Gentlesk, P., Grimaldi, M., Hansen, J., Hindricks, G., Al-Khalidi, H. R., Massaro, T., Mont, L., Nielsen, J. C., Nölker, G., Piccini, J. P., De Potter, T., . . . Di Biase, L. (2018). Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. European Heart Journal. https://doi.org/10.1093/eurheartj/ehy176

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.